within Pharmacolibrary.Drugs.ATC.H;

model H05BX04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.9166666666666667e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0052,
    k12             = 12.1,
    k21             = 12.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H05BX04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Etelcalcetide is a synthetic peptide calcimimetic agent used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) on hemodialysis. It acts as an agonist of the calcium-sensing receptor on parathyroid cells, thereby lowering parathyroid hormone (PTH) levels. Etelcalcetide is approved and currently used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with end-stage renal disease on hemodialysis, following intravenous administration.</p><h4>References</h4><ol><li><p>Wu, B, et al., &amp; Lee, E (2018). Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis. <i>Journal of clinical pharmacology</i> 58(6) 717–726. DOI:<a href=\"https://doi.org/10.1002/jcph.1090\">10.1002/jcph.1090</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29534286/\">https://pubmed.ncbi.nlm.nih.gov/29534286</a></p></li><li><p>Subramanian, R, et al., &amp; Skiles, GL (2017). Pharmacokinetics, Biotransformation, and Excretion of [. <i>Clinical pharmacokinetics</i> 56(2) 179–192. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0433-0\">10.1007/s40262-016-0433-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27517676/\">https://pubmed.ncbi.nlm.nih.gov/27517676</a></p></li><li><p>Xing, C, et al., &amp; Sohn, W (2021). A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis. <i>Clinical therapeutics</i> 43(11) 2013–2023. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2021.09.019\">10.1016/j.clinthera.2021.09.019</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34774334/\">https://pubmed.ncbi.nlm.nih.gov/34774334</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H05BX04;
